Welcome to our dedicated page for Balance Labs SEC filings (Ticker: BLNC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Balance Labs, Inc. files regular reports with the SEC as a publicly traded company on OTC Markets. These filings provide insight into the company's consulting operations, financial performance, and corporate governance.
Understanding Balance Labs' SEC Filings
For a micro-cap consulting firm, SEC filings reveal important details about revenue sources, client relationships, and operational expenses. Balance Labs' 10-K annual reports and 10-Q quarterly reports disclose how the company generates revenue from its business development services.
Key areas to examine in Balance Labs filings include:
- Revenue breakdown from consulting and development services
- Related party transactions with parent company Balance Holdings, LLC
- Operating expenses and cash flow from consulting operations
- Going concern statements and liquidity position
Form 4 Insider Transactions
Track insider buying and selling through Form 4 filings. For a small company like Balance Labs, insider transactions can represent significant ownership changes worth monitoring.
Material Events
8-K filings from Balance Labs disclose material events such as changes in management, significant contracts, or corporate restructuring. Our AI summaries help you quickly understand what each filing means for shareholders.
Balance Labs, Inc. reported a change in its board of directors. On December 12, 2025, director Carmen Villegas resigned from the board effective immediately.
The company states that Ms. Villegas’s decision to step down was not due to any disagreement with Balance Labs regarding its operations, policies, practices, controls, or financial-related matters. The filing does not describe any replacement or additional board changes.
Balance Labs, Inc. reported a larger net loss as it restructured leadership and recognized a new derivative tied to its CEO agreement. Net loss was $3,594,664 for Q3 2025 (basic and diluted EPS $0.16 loss) and $3,747,212 for the nine months ended September 30, 2025. Operating cash outflow was $93,487 for the nine months.
Liquidity remains strained: cash was $4,512 as of September 30, 2025, with a working capital deficit of $8,675,685 and an accumulated deficit of $9,630,533. Management disclosed substantial doubt about continuing as a going concern. A derivative liability of $3,297,695 was recognized from an anti‑dilution feature in the CEO’s employment agreement, with a $3,425,796 loss recognized and a $128,101 remeasurement gain in the quarter.
The company issued 780,264 shares to its CEO as part of an initial equity grant, recognizing $142,633 in stock‑based compensation in Q3. As a subsequent event, outstanding debt totaling $4,166,946.69 was converted into common stock at $0.25 per share, and the Board approved additional equity issuances at the same price. Shares outstanding were 46,852,319 as of November 13, 2025.
FAQ
What is the current stock price of Balance Labs (BLNC)?
What is the market cap of Balance Labs (BLNC)?
